Nuvation Bio Inc. (NUVB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.45: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 11.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 30.00; Below-average business quality.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It... Read more
Sell if holding. Engine safety override at $4.45: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 11.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 30.00; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 4d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
6 floor-breakers·2 ceiling hits
Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.45: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 11.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 30.00; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $4.12. Score 4.9/10, moderate confidence.
Take-profit target: $10.73 (+141.9% upside). Prior stop was $4.12. Stop-loss: $4.12.
Quality below floor (3.7 < 4.0).
Nuvation Bio Inc. trades at a P/E of N/A (forward 434.0). TrendMatrix value score: 3.6/10. Verdict: Sell.
17 analysts cover NUVB with a consensus score of 4.1/5. Average price target: $12.
What does Nuvation Bio Inc. do?Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer...
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.